{
    "pmcid": "8097376",
    "qa_pairs": {
        "How many unique nanobodies specific to the SARS-CoV-2 spike receptor-binding domain were identified in the study?": [
            "11",
            "8",
            "5",
            "14"
        ],
        "What are the key characteristics of nanobodies that make them suitable for therapeutic and diagnostic applications?": [
            "Small size, high stability, solubility, and rapid tissue penetration",
            "Large size, low stability, insolubility, and slow tissue penetration",
            "Small size, low stability, insolubility, and rapid tissue penetration",
            "Large size, high stability, solubility, and slow tissue penetration"
        ],
        "What is the significance of the biparatopic nanobody (bipNb) developed in the study?": [
            "It demonstrated viral neutralization efficacy in the picomolar range and showed potential for therapeutic application",
            "It was unable to bind to RBD mutants from SARS-CoV-2 variants",
            "It showed no potential for therapeutic application due to low binding affinity",
            "It was ineffective in neutralizing the virus in any concentration range"
        ],
        "What was the primary method used to select the nanobodies specific to the SARS-CoV-2 spike receptor-binding domain?": [
            "Phage display techniques",
            "CRISPR-Cas9 gene editing",
            "Yeast two-hybrid screening",
            "Mass spectrometry analysis"
        ],
        "Which SARS-CoV-2 variants did the biparatopic nanobody (bipNb) show cross-reactivity with?": [
            "B.1.1.7 (UK) and B.1.351 (South Africa)",
            "B.1.617.2 (India) and P.1 (Brazil)",
            "B.1.429 (California) and B.1.526 (New York)",
            "B.1.525 (Nigeria) and B.1.617.1 (India)"
        ]
    }
}